Bunionectomy Study
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Pain
Intervention: pregabalin (Drug); naproxen sodium (Drug); Comparator: Placebo (unspecified) (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
We are interested in whether bunionectomy can be used as a model to study the treatment of
acute pain. It has been used to study the effect of Non-Steroidal Anti-inflammatory (NSAIDS)
medications (such as ibuprofen) and other pain relieving drugs. We are interested to know if
this model is useful to study other drugs for the treatment of acute pain. The other drugs
being tested in this study are pregabalin and naproxen sodium. These drugs are approved for
use by the Food and Drug Administration (FDA). This study is designed to test whether these
two drugs are effective in treating pain after a bunionectomy.
Clinical Details
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Pregabalin and Naproxen Sodium on Postoperative Pain After Bunionectomy
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Reduction in the total dose of PCA hydromorphone use
Secondary outcome: Time to first request of PCA hydromorphone
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient is a man or woman between 18 and 65 years of age
- For Women of Child-bearing potential: woman who is currently not pregnant not nursing
and who is willing to use a medically acceptable method of birth control from the time
after the screening visit until completion of the follow-up visit
- Patient is scheduled to have a bunionectomy
- Patient must be willing to stay at the study site throughout the 48-hour observation
period following surgery and is willing to complete a 2-week follow up
- Patient is capable of operating a Patient Controlled Analgesia device
Exclusion Criteria:
- Patient is being treated for a disease and has not been on a stable dose of medication
for at least 2 weeks prior to surgery
- Patient has used or intends to use any of the medications that are prohibited by the
protocol, which could interfere with the evaluation of the study drugs
- Patient has an estimated creatinine clearance of < or = 60mL per min
- Patient has a history of drug abuse or dependence, or patient has a positive urine
drug screen
- Patient has a condition that prevents clear communication concerning pain perception
(such as diabetic neuropathy, peripheral neuropathy, etc.)
Locations and Contacts
Additional Information
Starting date: July 2007
Last updated: March 3, 2008
|
